Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Kazia Therapeutics Announced The Early Conclusion Based On Safety And Clinical Response Findings Observed To Date From A Two-part Phase 1 Trial Of Paxalisib With Radiation Therapy For PI3K Pathway Mutation Brain Metastases From Solid Tumors

Author: Benzinga Newsdesk | February 21, 2024 08:40am

Posted In: KZIA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist